Wassil Jim 4

4 · Vaxcyte, Inc. · Filed Apr 3, 2026

AI-generated summary of this filing

Updated Apr 3, 2026

Vaxcyte (PCVX) COO Wassil Jim Sells 2,250 Shares

What Happened

Wassil Jim, Chief Operating Officer of Vaxcyte, sold a total of 2,250 shares on April 1, 2026 in two open-market transactions: 1,412 shares at a weighted-average price of $58.14 ($82,091) and 838 shares at a weighted-average price of $58.93 ($49,385), for combined proceeds of about $131,476. These sales were reported on a Form 4 filed April 3, 2026.

Key Details

Transaction dates: April 1, 2026 (reported Apr 3, 2026; appears filed within the standard 2-business-day window).
Prices: weighted-average prices $58.14 (range $57.695–$58.69) and $58.93 (range $58.74–$59.215); full breakdown by price available upon request per the filing.
Total shares sold: 2,250; total proceeds ≈ $131,476.
Shares owned after transaction: Not specified in the provided Form 4.
Notable footnotes: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted Dec 9, 2025 (routine plan-based selling). The filing also notes prior transfers under a divorce settlement (962 and 612 shares transferred on Mar 25–26, 2026); those disposed shares will not be reported as beneficially owned in future Section 16 filings.

Context

These were sales (often routine for insiders, especially when executed under a pre-established 10b5-1 plan) and do not by themselves indicate company outlook. The filing includes a domestic relations order-related transfer in late March, which affected beneficial ownership reporting going forward.

Form 4

Period: 2026-04-01

CHIEF OPERATING OFFICER

Transactions

Footnotes (4)

[F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
[F2]The price reported is a weighted-average price. The shares were sold at prices ranging from $57.695 to $58.69. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F3]The price reported is a weighted-average price. The shares were sold at prices ranging from $58.74 to $59.215. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F4]The Reporting Person entered into a divorce settlement agreement with his ex-spouse (the "Settlement Agreement") pursuant to a "domestic relations order" as defined in Section 16(a)(12) of the Securities Exchange Act of 1934, as amended. On March 25 and 26, 2026, the Reporting Person transferred 962 and 612 shares, respectively, of Vaxcyte, Inc. Common Stock to his ex-spouse pursuant to the Settlement Agreement. Accordingly, the Reporting Person will not report beneficial ownership of or dispositions of the disposed shares in future Section 16(a) filings.

Signature

Jim Wassil, by /s/ Peter N. Efremenko, Attorney-In-Fact|2026-04-03

1 file